Generix Group - 2020/2021 Annual Results
02 Giugno 2021 - 6:01PM
Generix Group - 2020/2021 Annual Results
PRESS RELEASE
Paris, June 2, 2021
2020/2021
ResultsEbitda
Rate:
12%, in
line with profitability
objectivesR&D strategic
investments
Generix Group, Industrial, Logistics and
Retail Ecosystems provider with leading Collaborative SaaS
Solutions, today issued
its results for 2020/2021
fiscal year.
Key figures as of
March 31, 2021
|
Twelve months ended March 31, |
Variation |
IFRS consolidated accounts,
in millions of Euros (unaudited) |
2021 |
2020 |
M€ |
% |
Key elements of the consolidated income statement |
Revenues |
80,3 |
81,1 |
-
0,8 |
-1% |
EBITDA |
9,9 |
13,5 |
-
3,6 |
-27% |
Operating income |
7,1 |
9,5 |
-
2,4 |
-25% |
Financial result |
-
0,6 |
-
0,6 |
-
0,0 |
-4% |
Income taxes benefit |
-
1,4 |
-
5,4 |
4,0 |
-74% |
Net profit Group share |
5,0 |
3,4 |
1,6 |
47% |
Key elements of the consolidated Balance Sheet |
Net debt |
-
10,9 |
-
12,4 |
1,5 |
-12% |
Free cash flow |
4,4 |
7,0 |
-
2,6 |
37% |
A
resilient
business model, R&D strategic
investments
In a 2020/2021 financial year marked by an
unprecedented economic and health context, Generix Group recorded a
€80.3 million revenue (-1% vs. 2019/2020). Adjusted for exchange
rate volatility, revenues would show growth of 1%, driven in
particular by North America.
At the end of March 2021, EBITDA was €9.9
million, representing an EBITDA margin of 12.3%. The 4.4 point
decrease in EBITDA margin compared to the end of March 2020 is
almost entirely (4.1 points) the result of the additional
investment in R&D that the Group is implementing to respond to
the market potential revealed by the crisis. Indeed, production and
distribution systems have been subject to major disruptions linked
to supply disruptions and very erratic demand in terms of volume
and time. Changes in purchasing behavior and resource constraints
have had a major impact on production and distribution costs. These
changes have put supply chain back at the heart of companies'
strategies, and in this context Generix Group intends to
consolidate its leading position by completing its offer. Excluding
growth in R&D investments, the EBITDA margin will be down by a
limited 0.3 point, thanks to the adaptation of the cost structure
initiated in April 2020 to limit the impact of the health
crisis.
Non-cash items showed a positive trend, with
current operating income of €7.2 million, or 9% of revenues.
After taking into account non-recurring items,
financial income and the tax effect, net income was €5.1 million,
compared with €3.5 million the previous year. As a reminder, the
tax charge for the previous year was impacted by a negative €3.2
million by the updating of future tax rates in the calculation of
deferred taxes following the application of the preferential
industrial property regime (IP Box).
A healthy and solid financial
structure
For the fiscal year 2020/2021, cash flows are
mainly marked by:
-
A decrease in cash flow from operations from €12.4 million to €9.5
million as of March 31, 2021, to be compared with the decrease in
EBITDA observed during the year;
-
A significant improvement in working capital requirements, due in
particular to improvement in customer payment delays;
-
The acquisition of Generix Soft Group Romania for €3.4 million,
financed by a loan of €3.0 million.
Prospects
Continued momentum in the signing of new
contracts, as well as investments in R&D and development in
North America, enable the Group to anticipate double-digit growth
and a stable EBITDA margin for the 2021/2022 financial year.
Supplemental
and non-IFRS Financial Information
Supplemental non-IFRS
information (above-mentioned as EBITDA or net debt) presented in
this press release is subject to inherent limitations. It is not
based on any comprehensive set of accounting rules or principles
and should not be considered as a substitute for IFRS measurements.
Also, the Company’s supplemental non-IFRS financial information may
not be comparable to similarly titled non-IFRS measures used by
other companies.
Next financial press release: July 28, 2021
after the market closes
Revenues for the first quarter of financial year
2021/2022
About Generix Group
Generix Group is a
Collaborative Supply Chain expert present in 60 countries, thanks
to its subsidiaries and network of partners. More than 6,000
companies around the world use its SaaS solutions. The group’s 750
employees provide daily support for such customers as Carrefour,
Danone, FM Logistic, Fnac-Darty, Essilor, Ferrero and Geodis in the
digital transformation of their Supply Chain.
Its collaborative platform, Generix
Supply Chain Hub, helps companies to keep the promises
they make to their customers. It combines the capabilities to
execute physical flows, digitalize information flows, manage
collaborative processes and connect companies to all their
partners, in real time.
Generix Supply Chain Hub is
aimed at all players in the Supply Chain: manufacturers, third- and
fourth-party logistics providers (3PL/4PL) and retailers.
www.generixgroup.com
Founded in France in 1990, the company is listed
on the Eurolist market of Euronext Paris, compartment C (ISIN:
FR0010501692). To learn more: www.generixgroup.com
Appendices
|
Twelve months ended March 31, |
Variation |
IFRS consolidated accounts,
in millions of Euros (unaudited) |
2021 |
2020 |
M€ |
% |
Revenues |
80,3 |
81,1 |
-
0,8 |
-1% |
Other income from operations |
4,0 |
3,6 |
0,4 |
10% |
Operational expenses |
-
74,3 |
-
71,2 |
-
3,2 |
4% |
Other purchases and external charges |
-
18,2 |
-
21,9 |
3,7 |
-17% |
Personnel costs |
-
51,4 |
-
45,8 |
-
5,6 |
12% |
Taxes and similar payments |
-
2,0 |
-
1,6 |
-
0,4 |
24% |
Other |
-
2,7 |
-
1,8 |
-
0,9 |
50% |
EBITDA |
9,9 |
13,5 |
-
3,6 |
-27% |
EBITDA margin |
12% |
17% |
|
|
Software design costs activated net of depreciation |
0,9 |
0,5 |
0,4 |
85% |
Net depreciation and provisions |
-
3,0 |
-
3,7 |
0,7 |
-19% |
Expenses relative to free shares |
-
0,6 |
-
0,8 |
0,3 |
-32% |
Recurring operating income |
7,2 |
9,5 |
-
2,2 |
-24% |
Other operational income and expenses |
-
0,1 |
- |
-
0,1 |
N/A |
Operating income |
7,1 |
9,5 |
-
2,4 |
-25% |
Financial result |
-
0,6 |
-
0,6 |
-
0,0 |
-4% |
Income taxes benefit |
-
1,4 |
-
5,4 |
4,0 |
-74% |
Net result after tax |
5,1 |
3,5 |
1,6 |
46% |
Net
profit Group share |
5,0 |
3,4 |
1,6 |
47% |
(1) EBITDA = current operating income + net
provisions on assets + net provisions for risks and charges +
depreciation on fixed assets + charges related to free shares -
capitalized production costs. |
|
|
|
|
|
|
|
|
|
|
Twelve months ended March 31, |
Variation |
Net debt, in millions of
Euros (unaudited) |
2021 |
2020 |
M€ |
% |
Cash and cash equivalents, end of period |
14,5 |
12,5 |
2,0 |
16% |
Short-term and long-term portions of financial obligations |
-
25,4 |
-
24,9 |
-
0,5 |
2% |
Net debt |
-
10,9 |
-
12,4 |
1,5 |
-12% |
|
|
|
|
|
|
Twelve months ended March 31, |
Variation |
Consolidated statements of
cash flows, in millions of Euros (unaudited) |
2021 |
2020 |
M€ |
% |
Net income adjusted by non-cash items |
9,5 |
12,4 |
-
2,8 |
-23% |
Change in working capital |
2,0 |
-
1,7 |
3,7 |
-213% |
Net cash by operating activities |
11,5 |
10,6 |
0,9 |
8% |
Net cash used in investing activities |
-
7,1 |
-
3,6 |
-
3,5 |
96% |
Free cash flow |
4,4 |
7,0 |
-
2,6 |
-37% |
Net cash by financing activities |
-
2,4 |
-
3,6 |
1,2 |
-34% |
Currency effects |
-
0,0 |
-
0,1 |
0,1 |
-79% |
Net increase in cash and cash equivalent |
2,0 |
3,3 |
-
1,3 |
-40% |
Cash and cash equivalent, end of period |
14,5 |
12,5 |
2,0 |
16% |
- Generix Group - Annual Revenue - 2020-2021